S urgery constitutes the primary treatment modality for resectable thymomas. The role of radiation therapy (RT) for locally invasive but nonmetastatic (stages II and III) thymomas remains controversial. Previous studies have shown conflicting results regarding the role of adjuvant RT in resected thymoma. There are data that suggest RT can decrease the local recurrence rate and increase the 5-year overall survival (OS) from 18% to 62% in stages II to IVa thymoma. 1 In contrast, there are other studies that do not show a benefit in recurrence or survival for resected stage II thymoma. [2] [3] [4] [5] In current clinical practice, RT is often given in the adjuvant setting for higher Masaoka stages, incomplete resection, or positive resection margins. However, this practice remains controversial due to the conflicting clinical evidence. The goal of this study is to determine the effect of postoperative RT on the outcome of stages II and III thymoma patients treated at our institution.
MATERIALS AND METHODS

Patient Population, Adjuvant Radiation, and Follow-up
We retrospectively reviewed the medical records of 175 thymoma patients who were treated and followed from July 1996 to January 2013 at our institution. Potentially resectable patients underwent preoperative imaging, followed by surgical resection and subsequent referral for adjuvant therapy. Relapse within the surgery bed or radiation field was defined as a local recurrence; progression was defined as local recurrence and distant or systemic failure. Patients with r6 months of followup or without complete pathologic staging were excluded. Eighty-eight thymoma patients with adequate follow-up and met histologic criteria were included in this study.
Pathologic Staging and Margin Status
Staging was based on the modified surgical and pathologic criteria described by Masaoka et al 6 : stage I, macroscopically completely encapsulated and microscopically no capsular invasion; stage II, macroscopic invasion into surrounding fatty tissue or mediastinal pleura, or microscopic invasion into the capsule; stage III, macroscopic invasion into neighboring organs (pericardium, great vessels, or the lung); stage IVa, pleural or pericardial dissemination; and stage IVb, lymphogenous or hematogenous metastasis. Staging was retrospectively reviewed and confirmed by dual observer unblinded review based on the pathology reports and operative notes. Margin status (positive or negative) was retrospectively reviewed and confirmed by dual observer unblinded review based on the pathology reports.
Statistical Analysis
We used multivariate Cox regression models to examine the effect of covariates on OS and progression-free survival (PFS), including stage, margin status, and use of adjuvant radiation for all patients. Kaplan-Meier curves with the logrank test was used to compare surgery alone (S) versus surgery followed by radiotherapy (S + RT) on OS and PFS for stages II and III patients and after stratifying treatment groups by margin status. Pr0.05 was considered statistically significant. Survival time and time to progression were calculated from the date of surgery.
RESULTS
Patients Characteristics
Among the 175 thymoma patients treated and followed at our institutions from July 1996 to January 2013, 88 patients with complete staging, complete pathology (including resection margin status), and adequate follow-up were included. Among the 88 thymoma patients, 26 (30%) patients had myasthenia gravis (Table 1) . Of the 88 patients, 22 were stage II and 18 were stage III. The median follow-up time for stage II and III patients was 49 months. Of the 22 resected stage II patients, 10 (45%) received RT and 12 (55%) did not. The median radiation dose for stage II was 50.4 Gy (range, 45 to 55 Gy). Among the 18 stage III patients, 13 (72%) underwent surgery and RT, 2 (11%) underwent surgery only, 2 underwent surgery and adjuvant chemotherapy, and 1 received concurrent definitive chemoradiation. The median radiation dose for stage III was 59.4 Gy (range, 45 to 70 Gy). Margin-positive patients were more likely to receive RT. In the S alone group, 20% were margin positive, compared with 68% in the S + RT group (P < 0.001, Fisher exact test).
Prognostic Factors for OS and PFS
Positive surgical margins predicted for worse OS (hazard ratio [HR] = 7.1, P = 0.004, Table 2 ). None of the covariates was identified as an independent prognostic factor for PFS (Table 3) ; the 1 possible exception was positive margin status, for which the multivariate Cox model showed a trend toward a significantly increased HR for disease progression (HR = 5.5, P = 0.06, Table 3 ). Figure 1A shows the Kaplan-Meier curves for OS. Among stages II and III thymoma patients, the 5-year OS was 72.9% in S alone group and 88.4% in S + RT group. There was no statistically significant difference in OS when comparing S + RT versus S alone (log-rank test, P = 0.95). Figure 1B shows the Kaplan-Meier curves for PFS. Among stages II and III thymoma patients, the 5-year PFS was 59.3% in S alone group and 75.9% in S + RT group. There was no statistically significant difference in PFS when comparing S + RT versus S alone (log-rank test, P = 0.63).
Impact of RT on Clinical Outcomes
As shown in Figure 2A , among margin-positive stages II and III patients, OS was 81.5% at 5 years in the S + RT group, and 0% at 5 years for S alone group. Five-year OS was 100% Cox regression modeling showed that positive surgical margin predicted worse overall survival, (hazard ratio = 7.1, P = 0.004). Adjuvant radiation was not identified as a significant predictor for overall survival (P = 0.36). There was no statistically significant factor identified as an independent prognostic factor for disease progression; the hazard ratio of resection marginpositive patients approached significance at 5.47 (P = 0.06). Adjuvant radiation was not identified as a significant predictor for progression-free survival (P = 0.41).
in both S alone group and the S + RT group in margin-negative stages II and III patients (Fig. 2B ). Figure 2 shows the impact of S + RT versus S alone on OS stratified by margin status. The margin-positive stages II and III thymoma patients treated with S + RT had higher OS than S alone (log-rank test, P = 0.006); whereas, margin-negative stages II and III thymoma patients did not demonstrate any significant differences between S + RT versus S alone (log-rank test, P = 0.733). Figure 3 shows the impact of S + RT versus S alone on PFS stratified by margin status. No statically significant differences in PFS were observed between S + RT versus S alone in margin-positive (log-rank test, P = 0.467) or margin-negative (log-rank test, P = 0.847) stage II and III thymoma.
In terms of pattern of failure, among those stages II and III patients with positive margins who did undergo RT (13 patients), there were 3 patients who had local recurrence and no patient with distant failure detected by the end of the study time. Among those stages II and III patients with positive margins who did not undergo RT (8 patients), there were 2 patients who had local recurrence and 1 patient with distant failure by the end of the study time. Statistical analysis on the pattern of failure was not performed due to the limited sample size.
DISCUSSION
Studies of thymoma are challenging due to its relatively low incidence, a prolonged disease course, and the need for extended follow-up. Several large series have shown that the Masaoka staging correlated well with survival. [7] [8] [9] Other studies also showed that complete surgical resection is the most important prognostic factor for survival. 9, 10 There are no reported prospective studies so far to provide a definitive conclusion on the clinical benefits of adjuvant radiation in stages II and III thymoma patients, and retrospective studies so far have reported mixed results. [11] [12] [13] [14] [15] Several reported series by investigators at University of Pennsylvania, 2,5 Memorial Sloan Kettering Cancer Center, 4 Massachusetts General Hospital, 16 and University of Eastern Piedmont in Italy 17 showed no local control benefit of adjuvant radiation in stage II thymoma. Studies at Massachusetts General Hospital found that adjuvant radiation was not independently associated with disease progression on a multivariable analysis of stages II and III patients. 18 Similarly, this single-institutional retrospective study showed that adjuvant RT increased OS and PFS but this finding was not statistically significant. We did demonstrate improved OS in the subgroup of margin-positive patients. Previous studies have shown that complete surgical resection is the most important prognostic factor. 9, 10 Our study using Cox regression modeling showed that positive surgical margin was an independent factor associated with worse OS (HR = 7.1, P = 0.004). Given that the positive resection margin predicts for worse outcome and that most (69%) patients in the S + RT group had positive margins, it is possible that the effect of radiation may have been confounded by the higher number of patients with positive margins. To test this hypothesis, we compared the OS of resected stages II and III thymoma patients with or without RT separately for the margin-positive subgroups and the margin-negative subgroups. We found that for resection margin-positive stages II and III thymoma, S + RT resulted in a higher OS than S alone (P = 0.006); for resection margin-negative stages II and III thymoma, no statistically significant differences were observed between S + RT versus S alone (P = 0.733). The exact underlying mechanism for the difference in OS in the margin-positive patients who received and who did not receive RT is unknown. One possibility could be that RT eradicated and sterilized the positive resection margins, and thus delayed or prevented the local recurrence and/or metastasis process. This may have contributed to the improved OS in the group who received RT. For PFS, similar to OS, the Kaplan-Meier analyses showed a trend favoring the receipt of RT after surgery for both PFS and OS in margin-positive stages II and III thymoma patients. However, no statistically significant differences in PFS were observed between S + RT versus S alone in margin-positive (P = 0.467) stages II and III patients; again, likely owing to the limited patient numbers.
Several limitations apply to this single-institutional retrospective study. Because of its observational design, inherent selection bias could have confounded the results. There may be selection biases depending on referral patterns. More specifically, patients referred for RT could have been more likely to have tumors with characteristics associated with prognosis other than involved margins, including, for example, World Health Organization Classification of Thymoma and tumor size. Our study did not account for the potential impact of these other characteristics on survival outcomes. Patients were referred for adjuvant radiation at the discretion of the treating surgeons. Some patients with positive margins were not referred for RT due to surgeons' preference and variations in practice patterns. Because of the small sample size, limitations to reach statistically significant differences were also possible and our study was likely powered to only detect very large differences in survival outcomes. Furthermore, it is possible that some patients with positive resection margins did not receive postoperative RT due to poorer ECOG performance status, and variations in practice patterns among different institutions may limit the application of the single-institution results to other institutions. Despite these limitations, the observed impact of adjuvant RT on OS outcomes deserves further investigation in future prospective trials for stages II and III thymoma.
CONCLUSIONS
For stages II and III thymoma, adjuvant radiation after surgery did not lead to statistically significant differences in PFS or OS, but our results are limited by the small sample size. Postoperative radiation seemed to improve the OS in the subset of patients with positive resection margins, and therefore may be considered in this patient population.
